Hospital

Donna Bohannon, RPh, MS, principal scientist at US Pharmacopeia (USP), and Bhumi Khambholja, PharmD, MSHI, project manager of Wisconsin Health Literacy, discuss how to adopt USP standards for labeling to increase health equity.

Additionally, the ITT-E population showed both treatment arms showing a high proportion of participants with plasma HIV-1 RNA c/mL with dolutegravir/lamivudine demonstrating non-inferior virologic suppression to the TAF-based regimen.

Generic substitution can lower patient drug costs and improve medication adherence.

Among 38 patients with B-cell derived malignancies who were seronegative after 2 COVID-19 vaccine doses, 55% had detectable antibodies after the third dose whereas 45% remained seronegative.

Patients with relapsed or refractory chronic lymphocytic leukemia are generally divided by those exposed to Bruton's tyrosine kinase inhibitors (BTKi), patients relapsing after venetoclax, and patients relapsing after BTKi and B-cell lymphoma-2 inhibitors.

Although it may not be feasible in all situations, professional sabbatical leave could be a win-win for both pharmacists and their employers.

During atrial fibrillation, both of the heart's upper chambers beat chaotically and irregularly without coordination.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential adverse effects and drug-drug interactions with psilocybin, MDMA, and ketamine treatment.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what the role of the pharmacist is during the treatment of patients with advanced cutaneous T cell lymphoma.

The agency has given the greenlight to maralixibat after the ICONIC study combined with 5 years of supportive studies that demonstrated the reduction of pruritis.

Robert Z. Orlowski, MD, PhD, director of the Myeloma Section at the University of Texas MD Anderson Cancer Center, reviewed novel agents in the treatment of triple-class refractory myeloma during a session at the 2021 annual meeting of the Society of Hematologic Oncology (SOHO).

The recommendation for managing cytopenias among patients treated with tyrosine kinase inhibitors is to discontinue treatment at the onset of grade 3 or higher.

The combination of cetuximab and encorafenib resulted in a median overall survival of 8.4 months, compared to 5.4 months in the control arm among patients with colorectal cancer.

Although specialty pharmacies may be able to offer some of the services that a hub provider does, a hub can standardize patient and provider support across the network.

Amisulpride is a selective dopamine-2 and -3 receptor antagonist that inhibits postoperative nausea and vomiting.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses the areas that may need further investigation to progress advanced cutaneous T cell lymphoma treatments in the future.

Risk stratification for survival should not dictate treatment, but stratification for thrombosis risk should play an important role in treatment decisions.

Cemiplimab-rwlc is being developed by Regeneron and Sanofi under a global collaboration agreement.

Durvalumab in combination with oleclumab reduced the risk of non-small cell lung cancer disease progression or death by 56%, whereas patients receiving durvalumab and monalizumab had a 35% reduction.

The results were compared to those in the previous Pfizer-BioNTech study in people between 16 and 25 years of age who were immunized with 30 μg doses.

The combination maintained superior OS and response benefits versus sunitinib in both patients with intermediate- and poor-risk prognostic factors, the primary endpoint population, and across all randomized patients.

Vascepa is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients.

Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what research is underway in the advanced cutaneous T cell lymphoma field that she is currently keeping an eye on.

By deactivating a component of the MAPK signaling pathway, researchers were able to reduce the proportion of leukemia cells in blood and bone marrow.

Shawn Singh, CEO of VistaGen, discusses how to improve and more effectively treat mental health disorders for returning veterans, who currently account for 20% of all suicides in the United States.

Treatment of round pneumonia should be followed up with a 2-view chest X-ray weeks later.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), discusses the SHC’s recently released Flu DRIVE Toolkit, which was designed to help overburdened health systems improve flu vaccination rates among vulnerable populations.

An intravenous immunoglobulin option along with glucocorticoids could be effective in fighting drug-induced erythroderma for patients with AIDS.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, describes some of the challenges providers face during the treatment of patients with advanced cutaneous T cell lymphoma and how to address them.